CCR2 and Hepatic fibrosis: A CCR2 small interfering RNA silencing (siCcr2)-based therapy by loading multivalent siCcr2 with tetrahedron framework DNA nanostructure (tFNA) vehicle (tFNA-siCcr2) reduced inflammatory mediator production by blocking the NF-κB signaling pathway and attenuated liver fibrosis by regulating the immune cell function in animal experiment (108).